Who are Fecal Microbiota's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Clostridium butyricum capsules, Lactobacillus Fermentum, lactobacillus LB, INF108F probiotic, Lactobacillus Crispatus M247, Clostridium butyricum capsule.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fecal-microbiota.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Fecal Microbiota — Competitive Intelligence Brief

Fecal Microbiota (Fecal Microbiota) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biotherapeutic; microbiota restoration therapy. Area: Gastroenterology; Infectious Disease.

marketed Biotherapeutic; microbiota restoration therapy Gastroenterology; Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Fecal Microbiota (Fecal Microbiota) — University of California, San Francisco. Fecal microbiota transplantation (FMT) restores a healthy gut bacterial community by introducing donor microorganisms to treat dysbiosis-related conditions.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Fecal Microbiota TARGET	Fecal Microbiota	University of California, San Francisco	marketed	Biotherapeutic; microbiota restoration therapy
Clostridium butyricum capsules	Clostridium butyricum capsules	The Affiliated Hospital of Qingdao University	marketed	Live biotherapeutic agent
Lactobacillus Fermentum	Lactobacillus Fermentum	HEM Pharma Inc.	marketed	Live biotherapeutic / Probiotic
lactobacillus LB	lactobacillus LB	Hospital General de Mexico	marketed	Live biotherapeutic product / Probiotic
INF108F probiotic	INF108F probiotic	Massachusetts General Hospital	marketed	Live biotherapeutic product (probiotic)
Lactobacillus Crispatus M247	Lactobacillus Crispatus M247	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	marketed	Live biotherapeutic product
Clostridium butyricum capsule	Clostridium butyricum capsule	Xijing Hospital of Digestive Diseases	marketed	Live biotherapeutic agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biotherapeutic; microbiota restoration therapy class)

University of California, San Francisco · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fecal Microbiota — Competitive Intelligence Brief. https://druglandscape.com/ci/fecal-microbiota. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab